webinar register page

International Cancer Surveillance Projects: CONCORD-4 and VENUSCANCER

CONCORD: After describing world-wide surveillance of trends in cancer survival for the first time in 2015, the third cycle of the CONCORD programme (CONCORD-3) was updated to include patients diagnosed between 2000 and 2014, with follow-up to 31 December 2014. It included data for 18 cancers or haematological malignancies that collectively represented 75% of the global cancer burden in 2014. Individual patient records for over 37.5 million patients were included in the analyses. These data were provided by 322 population-based cancer registries in 71 countries and territories, of which 47 provided data with 100% national population coverage. Cancer registries in nine Canadian provinces and 42 US states contributed data for a total of 14,320,034 patients. Since 2017, the Organisation for Economic Cooperation and Development has included survival estimates from the CONCORD programme among the indicators of the effectiveness of health systems in managing cancer in all its Health at a Glance reports.

VENUSCANCER: Embedded in the CONCORD programme, this is a world-wide project designed to explain the global inequalities in patterns of care, short-term survival and trends in avoidable premature deaths from breast, cervical and ovarian cancers, the three most common cancers in women. The goal of this project, funded by the European Research Council, is to provide levers for health policy to reduce or eliminate avoidable differences in survival from these cancers.

During the webinar we will discuss the ongoing data submission to the VENUSCANCER project, and the recent call for data for CONCORD-4.

Presenters
Claudia Allemani, MSc, PhD, FHEA, MFPH
London Scholl of Hygiene and Tropical Medicine

Bozena Morawski, BA, MPH, PhD
Cancer Data Registry of Idaho

Michel Coleman, BA, BM BCh, MSc, FFPH
London School of Hygiene and Tropical Medicine

Christopher Johnson, MPH
Cancer Data Registry of Idaho

Mar 20, 2023 02:00 PM in Eastern Time (US and Canada)